K-numberK252228
Device nameSeaman Pro/Seaman
ApplicantCheckcells, Inc.
Product codePOV
Device classClass II
Decision dateApr 9, 2026
DecisionSubstantially Equivalent
Regulation864.5220
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Seaman PRO is an automated, point-of-care, in vitro diagnostic device for semen analysis performed by healthcare professionals. It consists of imaging hardware (light source, optics, USB camera) connected to a PC running AI-based software that quantifies sperm concentration, total and progressive motility, morphology, vitality, and pH to assess sperm quality in adult males.

Technological characteristics

The Seaman PRO uses a modular hardware configuration (camera + optics + PC with AI software) versus the predicate's integrated desktop analyzer. Both employ custom image analysis with machine learning for sperm detection, but the Seaman PRO's modular design does not impact functionality. The Seaman PRO additionally measures vitality (percentage live sperm), which is supplementary and does not change the core intended use.

Test standards cited

Testing was designed per CLSI guidelines, WHO laboratory manual requirements, and ISO 23640:2015 standards. Non-clinical studies evaluated repeatability, reproducibility, linearity, limits of blank/detection/quantification, interference, sample volume effects, and environmental/hardware stability. Clinical testing compared the device against established reference procedures using 300 human semen samples.

Substantial equivalence argument

Both devices are in vitro diagnostic systems for quantitative human semen analysis targeting similar point-of-care professional users. Core measurement parameters (sperm concentration, total/progressive motility, morphology, pH) are identical; vitality is an additional supplementary feature that does not raise new safety or effectiveness concerns. Optical imaging and AI-assisted image analysis technology is fundamentally equivalent, and clinical method comparison demonstrated strong agreement (correlation >0.90, regression slopes 0.90–1.10).

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →